$0.00
−54.02%Price chart
Sep 1Sep 8Sep 11Sep 21Sep 29Oct 5Oct 13Oct 16
Key dataOct 16, 2026
Open$0.01
From 52W high−96.52%
Volume65870.00
Market cap$21724.82
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 16, 2026
Open
$0.01
From 52W high
−96.52%
Volume
65870.00
Market cap
$21724.82
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.9x
P/E (TTM)
—
RSI (14)
44.4
MomentumView details →
1D Return
−54.02%
YTD Return
−92.69%
SummaryUpdated Jun 1, 2026
Cingulate Inc. (NASDAQ:CING) is a clinical-stage biopharmaceutical company founded in 2012 and headquartered in Kansas City, Kansas. The company went public in December 2021 and focuses on developing innovative treatments for neurological and psychiatric disorders. Cingulate is currently advancing multiple drug candidates through clinical trials, with its primary focus on attention-deficit/hyperactivity disorder (ADHD) treatments and anxiety disorders.
Similar companies
Latest newsMore news →